more rarely with extrathyroidal spread and advanced tumor stage at presentation. Papillary thyroid microcarcinoma without presentation with cervical metastasis (incidental) has a reported risk of mortality of < 1%, locoregional recurrence rates of 2% to 6%, and distant recurrence rates of 1% to 2%. 2 An estimated 10% mean autopsy rate in the United States could potentially translate into 32 million people with undiagnosed PTMC. The prevalence of thyroid cancer in the United States is 0.5 million, suggesting that < 2% of this subclinical reservoir has been diagnosed.
The death rate from PTC has remained stable for decades at 0.5 deaths per 1,000,000. The proportion of cancers that are large, lymph node-positive, or have distant metastases has markedly declined over time. The lack of increase in mortality reflects the low clinical aggressiveness of most PTC and brings into question the value of early PTC detection and treatment. Most PTMC do not evolve into PTC. 3 There are no randomized prospective trials for the treatment of PTMC. Historically there have been advocates for total thyroidectomy and lobectomy for PTMC. Surveillance, Epidemiology, and End Results database (1988) (1989) (1990) (1991) (1992) (1993) (1994) (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) found the disease-specific survival for PTMC as over 99% over 15 years, with no difference in outcome between lobectomy and total thyroidectomy. 4 The 2015 ATA guidelines 2 recommend that if surgery is chosen for patients with thyroid cancer < 1 cm without extrathyroidal extension and cN0, the initial surgical procedure should be a thyroid lobectomy unless there are clear indications to remove the contralateral lobe. The risks of total thyroidectomy are significantly greater than that for thyroid lobectomy. 2 Active surveillance is being offered to selected patients with prostate cancer, urethral cancer, and some nonHodgkin lymphomas. Although PTMCs have high rates of multifocality and lymph node metastasis, it has been questioned if this leads to clinical disease development. Active surveillance of PTMC has been reported in Japan. Ito et al. followed 340 patients with PTMC with nonoperative surveillance if there was no tumor adjacent to the trachea or posterior thyroid, no high-grade malignancy, no regional metastasis, and no signs of progression. 3 Patients who had a 3-mm growth underwent surgery. This group had a 6% 3 Patients followed for 60 months found those < 40 had an 8.9% rate of progression. There was a 3.5% rate of progression for those patients 40 to 60 years old, and a 1.6% rate for those > 60. This suggests a subgroup of older patients who may be more amenable to observation, although younger patients also did well for the study period. 3 The 2015 ATA guidelines 2 no longer recommend biopsy for thyroid nodules less than 1 cm, even if ultrasonography is suspicious, without high-risk features such as cervical adenopathy or extrathyroidal invasion. The 2015 ATA guidelines 2 also endorse active surveillance for very low-risk tumors, such as PTMC without evident metastasis, local invasion, high-risk cytological features, or molecular characteristics.
Brito et al. 5 have developed a classification system (Table I ). An ideal patient for active surveillance would be an older patient with a solitary PTMC with a well-defined nodule margin not adjacent to the thyroid capsule. An appropriate but not ideal candidate may be younger, with multifocal disease, and with disease adjacent to the thyroid capsule at noncritical locations. Ideal patients have a 1% to 2% risk of progression, whereas appropriate patients have a 10% risk of progression. 3 An inappropriate candidate for active surveillance has tumor in critical subcapsular locations (adjacent to the recurrent laryngeal nerve or trachea), has evidence of spread outside the thyroid by either direct extension or metastases, or has evidence of disease progression on serial examinations. Active surveillance requires the ability to critically assess the tumor/ultrasonographic characteristics, an experienced medical team, and appropriate patient/family attributes.
BEST PRACTICE
A trend toward more conservative surgical management with lobectomy prevails over total thyroidectomy for surgical management. Active surveillance in selected low-risk patients (ideal patient is older with unifocal disease) is an attractive alternative. There is a lack of data on clinical, psychological, and economic effect of active surveillance. The potential need for thyroidectomy in younger patients undergoing prolonged surveillance and the long-term cost of active surveillance may be greater than that of initial lobectomy for patients with PTMC. Studies to define frequency of U.S. evaluation, optimal thyroid-stimulating hormone levels, potential use of thyroglobulin measurement, and indications for surgical intervention are needed.
LEVEL OF EVIDENCE
Level 2a for reference 3. Level 4 for other references. 
